Jafron Biomedical Co.,Ltd.

Shenzhen Stock Exchange 300529.SZ

Jafron Biomedical Co.,Ltd. Price to Book Ratio (P/B) on January 14, 2025: 7.14

Jafron Biomedical Co.,Ltd. Price to Book Ratio (P/B) is 7.14 on January 14, 2025, a 41.74% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Jafron Biomedical Co.,Ltd. 52-week high Price to Book Ratio (P/B) is 9.46 on October 08, 2024, which is 32.57% above the current Price to Book Ratio (P/B).
Jafron Biomedical Co.,Ltd. 52-week low Price to Book Ratio (P/B) is 4.14 on February 05, 2024, which is -42.01% below the current Price to Book Ratio (P/B).
Jafron Biomedical Co.,Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 6.60.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Shenzhen Stock Exchange: 300529.SZ

Jafron Biomedical Co.,Ltd.

CEO	Mr. Fan Dong
IPO Date	Aug. 2, 2016
Location	China
Headquarters	No. 98 Keji 6th Road
Employees	2,408
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials Medical Instruments

Description

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and marketing of biological materials and medical devices in China. It offers solutions for kidney, liver, critical, and rheumatism diseases, as well as poisoning; adsorption products and blood purification machines; and other products, such as single use arteriovenous puncture, hemodialysis online dry powder bags/cylinders, disinfectants, hemodialysis concentrates, and medical adsorbable suture with needles. The company offers its products in Germany, Italy, Turkey, Thailand, Vietnam, the Philippines, South Africa, Kenya, Chile, Peru, and the United Arab Emirates. Jafron Biomedical Co.,Ltd. was founded in 1989 and is based in Zhuhai, China.

Key trends

Past 5 years